Hikma Must Share Vascepa Copy Records as High Court Weighs Case

Hikma Pharmaceuticals Plc must produce launch records and make its generic-Vascepa product manager sit for deposition, an unsealed order in Amarin Pharma Inc.’s federal patent-infringement suit said.

Magistrate Judge Sherry R. Fallon’s Jan. 6 order, unsealed Tuesday in the US District Court for the District of Delaware, rejected Hikma’s request to block further questioning about how its generic Vascepa first went to market. Amarin, she said, is entitled to custodial documents and testimony from Steven Simone, the Hikma manager identified in other depositions as central to launch planning, sales training, and forecasting.

The ruling lands as the US Supreme ...